Navigating Multiple Myeloma Treatment Challenges

This chapter examines the intricate treatment landscape for multiple myeloma, focusing on factors influencing second transplants, the management of novel therapies, and evolving strategies with bispecific antibodies. It highlights recent advancements such as the FDA approval of Talcuetamab and insights into patient-specific treatment regimens for those facing refractory disease. The discussion emphasizes the importance of personalized approaches, addressing both efficacy and safety in managing the unique challenges presented by high-risk patients.